TerminatedPhase 3NCT04707703

Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis

Studying Aspergillosis

Last synced from ClinicalTrials.gov May 4, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Jeffrey Jenks, MD, MPH
Principal Investigator: Jeffrey Jenks, MD, MPH
University of California, San Diego
Intervention: Isavuconazonium Injection [Cresemba](drug)
Enrollment: 8 enrolled
Eligibility: 18 years · All sexes
Timeline: 2021 – 2021

Study locations (3)

University of California Irvine, Orange, California, United States
University of California Davis, Sacramento, California, United States
University of California San Diego, San Diego, California, United States

Collaborators

Astellas Pharma Global Development, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04707703 on ClinicalTrials.gov

Other trials for Aspergillosis

Additional recruiting or active studies for the same condition.

See all trials for Aspergillosis →

← Back to all trials